Blue Water Biotech Issues Letter to Shareholders
30 oct. 2023 07h00 HE
|
Blue Water Biotech, Inc.
CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer...
Insulin Pumps Market is Expected to Reach US$ 13.34 Billion By 2032
14 août 2023 04h21 HE
|
FACT.MR
Rockville, Aug. 14, 2023 (GLOBE NEWSWIRE) -- According to the new market research report, titled, "Insulin Pumps Market By Type (Tethered Pumps, Patch Pumps), By Accessory (Infusion Set Insertion...
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
25 juil. 2023 09h00 HE
|
Blue Water Biotech, Inc.
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and...
Benign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032
20 juil. 2023 10h45 HE
|
Acumen Research and Consulting
LOS ANGELES, July 20, 2023 (GLOBE NEWSWIRE) -- The Benign Prostatic Hyperplasia Therapeutics Market is witnessing significant growth due to the increasing prevalence of BPH and the rising demand for...
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
17 juil. 2023 09h00 HE
|
Blue Water Biotech, Inc.
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and...
Benign Prostatic Hyperplasia Treatment Market Size to Reach USD 18.1 Billion by 2032, at 5.50% CAGR – Report by Market Research Future (MRFR)
13 juil. 2023 05h46 HE
|
Market Research Future
New York, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Benign Prostatic Hyperplasia Treatment Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Benign...
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
11 juil. 2023 09h00 HE
|
Blue Water Biotech, Inc.
CINCINNATI, July 11, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and...
Benign Prostatic Hyperplasia Treatment Market to Grow at a 5.6% CAGR from 2023 to 2031, reaching US$ 11.9 billion: TMR Report
22 juin 2023 08h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 22, 2023 (GLOBE NEWSWIRE) -- The global benign prostatic hyperplasia treatment market is anticipated to grow at a 5.6% CAGR from 2023 to 2031. A market...
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
21 juin 2023 07h30 HE
|
Blue Water Biotech, Inc.
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today...
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
10 mai 2023 12h15 HE
|
Blue Water Biotech, Inc.
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global...